BioRestorative Therapies, Inc. (BRTX) Financial Statements (2026 and earlier)

Company Profile

Business Address 40 MARCUS DRIVE
MELVILLE, NY 11747
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 809 - Miscellaneous Health And Allied Services, Not (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,9534,4907,3819,11310,73313,088
Cash and cash equivalent1,5116021,5551,2295481,489
Short-term investments1,4423,8875,8267,88410,18511,598
Receivables16131525188165
Deferred costs 5069  14922
Other undisclosed current assets11913520221775234
Total current assets:3,1374,7077,5989,35511,14413,509
Noncurrent Assets
Operating lease, right-of-use asset      40
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization359309340370363378
Intangible asset, including goodwill, after accumulated amortization534557579602624646
Intangible asset, excluding goodwill, after accumulated amortization534557579602624646
Deferred costs 107  10 
Other undisclosed noncurrent assets 4062  138 
Total noncurrent assets:9439359199721,1361,065
TOTAL ASSETS:4,0805,6438,51710,32712,28014,573
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,3241,4671,0918771,2281,084
Accounts payable1,341860610600483401
Accrued liabilities982607481278744682
Deferred revenue    150  
Derivative instruments and hedges, liabilities 1,3991,9682,5803,1552,5213,456
Other undisclosed current liabilities      42
Total current liabilities:3,7233,4363,6714,1823,7484,582
Noncurrent Liabilities
Total liabilities:3,7233,4363,6714,1823,7484,582
Equity
Equity, attributable to parent, including:3572,2074,8456,1458,5319,992
Preferred stock  141414 14
Common stock111111
Additional paid in capital170,263168,905168,505167,149164,195164,020
Accumulated deficit(169,921)(166,713)(163,675)(161,019)(155,679)(154,043)
Other undisclosed equity, attributable to parent 14   14 
Total equity:3572,2074,8456,1458,5319,992
TOTAL LIABILITIES AND EQUITY:4,0805,6438,51710,32712,28014,573

Income Statement (P&L) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues20123032543234
Cost of revenue
(Cost of Product and Service Sold)
(2)(11)(9)(3)(3)(18)
Gross profit:1812952240215
Operating expenses(3,843)(3,710)(3,600)(4,830)(2,730)(2,502)
Operating loss:(3,825)(3,709)(3,305)(4,808)(2,690)(2,287)
Nonoperating income (expense)618671649(532)1,0541,196
Loss from continuing operations before equity method investments, income taxes:(3,208)(3,038)(2,656)(5,340)(1,636)(1,091)
Other undisclosed income from continuing operations before income taxes 41     
Net loss:(3,166)(3,038)(2,656)(5,340)(1,636)(1,091)
Other undisclosed net loss attributable to parent (41)     
Net loss available to common stockholders, diluted:(3,208)(3,038)(2,656)(5,340)(1,636)(1,091)

Comprehensive Income ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net loss:(3,166)(3,038)(2,656)(5,340)(1,636)(1,091)
Comprehensive loss, net of tax, attributable to parent:(3,166)(3,038)(2,656)(5,340)(1,636)(1,091)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: